Content provided by Nusano. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nusano or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App Go offline with the Player FM app!
<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/talkin-politics-religion-without-killin-each-other">Talkin‘ Politics & Religion Without Killin‘ Each Other</a></span>
Politics and Religion. We’re not supposed to talk about that, right? Wrong! We only say that nowadays because the loudest, most extreme voices have taken over the whole conversation. Well, we‘re taking some of that space back! If you’re dying for some dialogue instead of all the yelling; if you know it’s okay to have differences without having to hate each other; if you believe politics and religion are too important to let ”the screamers” drown out the rest of us and would love some engaging, provocative and fun conversations about this stuff, then ”Talkin‘ Politics & Religion Without Killin‘ Each Other” is for you!
Content provided by Nusano. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nusano or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed? Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape. Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer. Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer. Brought to you by the team at Nusano.
Content provided by Nusano. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Nusano or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed? Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape. Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer. Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer. Brought to you by the team at Nusano.
On this episode of Talk Radioisotopes, Scott and Sarah are joined by Dr. Shamar Young, Chief Medical Officer at TeleDaaS and Division Chief of Interventional Radiology at the University of Arizona. The discussion explores Dr. Young’s journey into interventional radiology, his expertise in Yttrium-90 (Y90) therapy, and the evolving role of precision dosimetry in radiopharmaceutical treatments. He highlights the challenges of implementing personalized dosimetry, the benefits of outsourcing these services through TeleDaaS, and the growing impact of Theranostics in cancer care. Dr. Young also shares insights into patient perceptions of radiation therapy, the rapid advancements in radiopharmaceutical research, and the increasing demand for personalized treatment approaches. The episode wraps up with a look at the future of radiopharmaceuticals, the barriers hospitals face in adopting new treatments, and what’s next for the field over the next five years. —----- Time Stamps: *(01:47) Revolutionizing Patient Care *(04:14) TeleDaaS: Dosimetry as a Service *(14:03) Patient Perspectives and Misconceptions *(17:10) Clinical Trials and Future of Radiopharmaceuticals *(21:59) Challenges and Future Outlook -------- ‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com . -------- Links: Follow Shamar on LinkedIn Visit TeleDaaS Talkradioisotopes.com —----…
In this episode of Talk Radioisotopes, hosts Scott and Sarah welcome Bruno Paquin, CEO of AtomVie Global Radiopharma. Bruno delves into the complexities and advancements of the radiopharmaceutical industry. The discussion highlights AtomVie’s role as a leading contract development and manufacturing organization (CDMO), their cutting-edge work in cancer care, and the innovative new facility being built in Hamilton, Ontario. Key topics include isotope sourcing, the development and scaling of radiopharmaceutical processes, logistic challenges, and the future of the industry. Bruno also addresses the demand for newer isotopes, the importance of early-stage collaboration, and the need to move radiopharmaceuticals up the treatment line for better patient outcomes. —----- Time Stamps: *(02:04) AtomVie: A Unique CDMO *(06:17) Isotope Production vs. Manufacturing *(13:07) When Good Science meets Good Infrastructure *(15:16) AtomVie's New Facilities and Their Impact *(23:08) From Hamilton, Ontario to Point B *(30:48) Demand for Once-Theoretical Isotopes *(33:57) Bruno's Outlook on the Future of Isotope Supply -------- ‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com . -------- Links: Follow Bruno on LinkedIn Visit AtomVie Talkradioisotopes.com --------…
On this episode of Talk Radioisotopes, hosts Scott Larrivee and Sarah Scouten interview Arjun Murthy, co-founder of Maven Bio, an AI-driven biopharma market intelligence platform. They explore how Arjun's background, along with Maven Bio's technology, is transforming data analysis and research in the biopharma sector. Key topics include how AI is aiding radiopharmaceutical research, the importance of robust supply chains, and potential future developments in cancer treatment. Arjun shares insights on the role of AI in competitive intelligence, market research, and product planning within the complex biopharma industry. ----- Time Stamps: *(02:04) What Can Consultants and Platforms Add to the Conversation? *(06:06) AI: A Synthesis of Intelligence *(13:34) Maven Bio's Start with Y Combinator *(16:34) Digging into Radiopharmaceutical Data *(20:35) M&A and Supply Chain in 2025 *(25:22) The Next Five Years in Radiopharma ----- ‘Talk Radioisotopes: Going Nuclear on Cancer ’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com . ------ Links: Follow Arjun on LinkedIn Visit Maven Bio Talkradioisotopes.com -----…
On this episode, hosts Scott and Sarah sit down with Shaemus Gleason, Executive Vice President at Clarity Pharmaceuticals. The discussion highlights Shaemus's journey through the radiopharmaceutical industry, Clarity's innovations, and breakthroughs involving copper-based compounds for cancer treatment. Shaemus shares insights on the importance of chelators, supply chain logistics, and diagnostic imaging, emphasizing the need for universal patient access and the evolution of personalized medicine. The episode concludes with an optimistic outlook on the industry's future and things to look out for in the future. —----- Time Stamps: *(01:18) Building a Career in Radiopharma *(05:54) Racing against the half-life *(09:17) Clarity and Chelation *(14:52) Theranostic Parings *(20:19) Picking Winners: The Pathway to Commercial Development *(27:19) What Makes A "Good Responder"? *(30:36) Making it Easy for the Patient *(39:01) The Renaissance of Radiopharma -------- ‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano , a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com . -------- Links: Follow Shaemus on LinkedIn Visit Clarity Pharmaceuticals Talkradioisotopes.com —----…
On our first episode of ‘Talk Radioisotopes: Going Nuclear on Cancer,' host Scott Larrivee is joined by co-host Dr. Sarah Scouten and guest Jeff Jones of Oppenheimer & Company. The discussion covers the latest trends in the radiopharmaceutical and radiotherapeutics markets, including the rise of targeted radiotherapies, the involvement of large pharmaceutical companies, and key developments in isotope supply chains. Jeff provides insights from Oppenheimer's recent summit on radiotherapy, covering emerging technologies, new isotopes, and the regulatory and logistical challenges ahead. Sarah discusses the broader implications for the oncology field and the importance of clinician and infrastructure readiness. The episode concludes with a look ahead to 2025, discussing potential advancements, technological innovations, and how the political landscape might impact the future of cancer treatments. —----- Time Stamps: *(01:55) Jeff's 20 Year Career in Biotech *(07:12) The Infamous Oppenheimer Chart *(09:59) 9 Billion in Acquisitions *(16:58) Finding the right isotope for each patient *(19:19) Up-and-coming Isotopes *(23:18) How Prepared is the Industry? *(29:27) The Regulatory Environment of Radiotherapeutics *(33:53) The Next 5 Years of Radiopharmaceuticals -------- ‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano , a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com . -------- Links: Follow Jeff on LinkedIn Visit Oppenheimer.com Talkradioisotopes.com -------…
Radioisotopes are revolutionizing how cancers are detected and treated. But how do they work? And where is this field headed? Whether you’re a healthcare professional, researcher, pharma exec, or industry analyst, this podcast is a go-to resource for the rapidly evolving radiopharmaceuticals landscape. Welcome to Talk Radioisotopes: Going Nuclear on Cancer. We’ll take a look at the latest insights, trends and developments working to change patient outcomes and supply the fight against cancer. Join host Scott Larrivee and experts from across the industry, as they break down the science, shed light on real-world opportunities, and take a peek behind the curtain at the people, companies, and programs driving innovation in nuclear medicine. This is Talk Radioisotopes: Going Nuclear on Cancer. Brought to you by the team at Nusano.…
Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.